Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Sells $320,634.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush sold 17,813 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $18.00, for a total transaction of $320,634.00. Following the transaction, the chief technology officer now directly owns 147,615 shares in the company, valued at $2,657,070. The trade was a 10.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA opened at $17.55 on Friday. The company’s fifty day moving average is $16.62 and its two-hundred day moving average is $13.51. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -11.47 and a beta of 1.52. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals plc has a 52-week low of $6.65 and a 52-week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. Equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after acquiring an additional 1,509 shares during the period. Quarry LP boosted its position in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after acquiring an additional 3,108 shares in the last quarter. Sandia Investment Management LP bought a new stake in Centessa Pharmaceuticals in the second quarter valued at about $90,000. Finally, Fred Alger Management LLC bought a new stake in Centessa Pharmaceuticals in the second quarter valued at about $99,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CNTA has been the subject of several recent research reports. Jefferies Financial Group boosted their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. BMO Capital Markets increased their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Finally, Guggenheim raised their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.